Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

March’s top news stories

Arrowhead Pharmaceuticals dosed the first subject in a Phase I/II clinical trial of ARO-HBV for the treatment of patients with chronic hepatitis B virus (HBV) infection, and CSL Behring started AEGIS-II Phase III clinical trial of CSL112 to reduce early recurrent cardiovascular events after an acute myocardial infarction (MI). Drugdevelopment-technology.com wraps up the key headlines from March 2018.

Go Top